Market closed
Citius Pharmaceuticals/$CTXR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Citius Pharmaceuticals
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Ticker
$CTXR
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
22
Website
CTXR Metrics
BasicAdvanced
$69M
Market cap
-
P/E ratio
-$0.24
EPS
1.68
Beta
-
Dividend rate
Price and volume
Market cap
$69M
Beta
1.68
52-week high
$1.07
52-week low
$0.31
Average daily volume
908K
Financial strength
Current ratio
6.745
Quick ratio
4.314
Long term debt to equity
0.098
Total debt to equity
0.371
Management effectiveness
Return on assets (TTM)
-24.74%
Return on equity (TTM)
-41.49%
Valuation
Price to book
0.81
Price to tangible book (TTM)
4.08
Price to free cash flow (TTM)
-2.138
Growth
Earnings per share change (TTM)
18.33%
3-year earnings per share growth (CAGR)
-4.28%
What the Analysts think about CTXR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Citius Pharmaceuticals stock.
CTXR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CTXR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Citius Pharmaceuticals stock?
Citius Pharmaceuticals (CTXR) has a market cap of $69M as of November 08, 2024.
What is the P/E ratio for Citius Pharmaceuticals stock?
The price to earnings (P/E) ratio for Citius Pharmaceuticals (CTXR) stock is 0 as of November 08, 2024.
Does Citius Pharmaceuticals stock pay dividends?
No, Citius Pharmaceuticals (CTXR) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Citius Pharmaceuticals dividend payment date?
Citius Pharmaceuticals (CTXR) stock does not pay dividends to its shareholders.
What is the beta indicator for Citius Pharmaceuticals?
Citius Pharmaceuticals (CTXR) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.